Impact of mixed‐infection rate of clarithromycin‐susceptible and clarithromycin‐resistant Helicobacter pylori strains on the success rate of clarithromycin‐based eradication treatment

Abstract

AbstractBackgroundClarithromycin (CAM) resistance is a major contributor to the failure to eradicate Helicobacter pylori (H. pylori). The mixed‐infection ratio of CAM‐susceptible and CAM‐resistant H. pylori strains differs among individuals. Pyrosequencing analysis can be used to quantify gene mutations at position each 2142 and 2143 of the H. pylori 23S rRNA gene in intragastric fluid samples. Herein, we aimed to clarify the impact of the rate of mixed infection with CAM‐susceptible and CAM‐resistant H. pylori strains on the success rate of CAM‐containing eradication therapy.Materials and MethodsSixty‐four H. pylori‐positive participants who received CAM‐based eradication therapy, also comprising vonoprazan and amoxicillin, were enrolled in this prospective cohort study. Biopsy and intragastric fluid samples were collected during esophagogastroduodenoscopy. H. pylori culture and CAM‐susceptibility tests were performed on the biopsy samples, and real‐time PCR and pyrosequencing analyses were performed on the intragastric fluid samples. The mutation rates and eradication success rates were compared.ResultsThe overall CAM‐based eradication success rate was 84% (54/64): 62% (13/21) for CAM‐resistant strains, and 95% (39/41) for CAM‐sensitive strains. When the mutation rate of the 23S rRNA gene was 20% or lower for both positions (2142 and 2143), the eradication success rate was 90% or more. However, when the mutation rate was 20% or higher, the eradication success rate was lower (60%).ConclusionsThe mutation rate of the CAM‐resistance gene was related to the success of eradication therapy, as determined via pyrosequencing analysis.